Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

These were the most-read FDA approval stories that were part of our coverage in 2024, brought to you as part of NeurologyLive®'s Year in Review.

NeurologyLive® Year in Review 2024: Most-Read FDA Approval Stories

As part of NeurologyLive®'s Year in Review, we've compiled the top coverage stories from 2024 across a variety of different neurological conferences the team either attended or covered virtually. 

NeurologyLive® Year in Review 2024: Top Conference Coverage Stories

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2024.

NeurologyLive® Year in Review 2024: Most-Read Features

With new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.

Advancing the Diagnostic Criteria for Multiple Sclerosis: A New Era of Early Detection and Precision 

, has been with the team since September 2022. Follow her on Twitter 

IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

IJMSC Insights: Ahmed Zayed Obeidat on the Intersection of Art and Medicine

Assistant professor of pediatrics at the University of Michigan.

Videos

A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]

Improving Access and Reducing Latency in Genetic Testing for Epilepsy: Julie Ziobro, MD, PhD; John Schreiber, MD

Assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona discussed an ongoing early-stage study assessing the therapeutic potential of NRTX-1001 nerve cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy. [WATCH TIME: 5 minutes]

Studying Nerve Cell Therapy NRTX-1001 to Treat Mesial Temporal Lobe Epilepsy: Jonathan Parker, MD, PhD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

AES 2024

CTAD 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

1rem

An expert neurologist discusses the use of targeted therapies to personalize treatment for patients with generalized myasthenia gravis (gMG) and reviews the impact on quality of life, the challenges of managing the disease, as well as new and emerging therapies.

Personalizing Myasthenia Gravis Treatment with Targeted Therapies

A physician expert discusses the socioeconomic burden of gMG on both the patient and the caregiver.

Impact of Generalized Myasthenia Gravis (gMG) on Quality of Life

An expert comments on the impact of factors such as disease course, antibody status, and patient adherence on the management of gMG.

Considerations for Approaching the Management of gMG

An expert reviews targeted therapies in generalized myasthenia gravis, highlighting complement and neonatal Fc receptors.

Therapeutic Strategies in gMG

An expert neurologist comments on the need for generalized myasthenia gravis treatment to be tailored to the patient to alleviate symptoms without significant adverse effects.

Personalizing gMG Treatment

James F. Howard Jr, MD, discusses both intravenous and subcutaneous efgartigimod for the treatment of gMG.

Subcutaneous Efgartigimod for Treatment of gMG

An expert neurologist reviews efficacy and safety data of rozanolixizumab, an FcRn-targeting agent approved for treatment of gMG, as well as how it differs from efgartigimod.

Other FcRn Targeting Agents gMG

James F. Howard Jr, MD, shares thoughts on the future of the treatment of gMG, highlighting the renewed interest in the disease landscape.

Future of gMG Treatment